Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab therapy.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 21785048.
- Also identified by DOI 10.2214/AJR.10.6032.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The objective of this article is to illustrate examples of radiologic immune-related response criteria and toxicity in patients with advanced melanoma treated with the immunotherapeutic agent ipilimumab. Novel immune-related tumor response criteria should be applied to patients undergoing therapy with ipilimumab for advanced melanoma. Ipilimumab also produces a spectrum of immune-related adverse effects that can be recognized radiologically.
Medical subject headings
- Antibodies, Monoclonal
- Drug-Related Side Effects and Adverse Reactions
- Immunotherapy
- Melanoma
- Skin Neoplasms
- Tomography, X-Ray Computed